Similar articles

• Effects of Apatinib Mesylate Monotherapy on the Incidence of Adverse Reactions and Immune Function in Patients with Breast Cancer after Radical Mastectomy.

  Lin S, Zang M. Lin S, et al. Evid Based Complement Alternat Med. 2022 Aug 10;2022:4022282. doi: 10.1155/2022/4022282. eCollection 2022. Evid Based Complement Alternat Med. 2022. Retraction in: Evid Based Complement Alternat Med. 2023 Dec 6;2023:9861238. doi: 10.1155/2023/9861238. PMID: 35990841 Free PMC article. Retracted.
• [Clinical observation of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer].

  Lü HM, Zhang MW, Niu LM, Zeng HA, Yan M. Lü HM, et al. Zhonghua Yi Xue Za Zhi. 2018 Apr 24;98(16):1246-1249. doi: 10.3760/cma.j.issn.0376-2491.2018.16.012. Zhonghua Yi Xue Za Zhi. 2018. PMID: 29747313 Chinese.
• Retracted: Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma.

  International EM. International EM. Emerg Med Int. 2024 Jan 24;2024:9795276. doi: 10.1155/2024/9795276. eCollection 2024. Emerg Med Int. 2024. PMID: 38298972 Free PMC article.
• Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review.

  Liu YY, Chen T, Shen D, Zhang WY, Wang CG, Jiang JH, Zeng DX. Liu YY, et al. J Int Med Res. 2020 Mar;48(3):300060519887276. doi: 10.1177/0300060519887276. Epub 2019 Dec 18. J Int Med Res. 2020. PMID: 31847652 Free PMC article. Review.
• Association of Apatinib and Breast Cancer: A systematic review and meta-analysis.

  Wang H, Su W, Lowe S, Zhou Z, Bentley R, Zhou Q, Cheng C, Guo X, Song Q, Liang Q, Li N, Liang M, Zhu Y, Sun C. Wang H, et al. Surg Oncol. 2022 Sep;44:101818. doi: 10.1016/j.suronc.2022.101818. Epub 2022 Jul 19. Surg Oncol. 2022. PMID: 35930900 Review.